Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

Our industry leading speaker faculty:

To find out what each speaker will be sharing their wisdom on, download your copy of the brochure here.


Riad Dirani

Riad Dirani

VP Global Health Economics and Outcomes Research, TEVA

Read more

More information coming soon...

John Bardi

John Bardi

Vice President Public Affairs and Digital Medicine Business Development, Otsuka

Read more

John Bardi is Vice President, Government Affairs, & Digital Medicines Business Development at Otsuka America Pharmaceutical, Inc. (OAPI). John oversees strategic business development for Otsuka's digital platform as well as the execution of government policy and advocacy.

Before joining Otsuka, John worked as Vice President, U.S. Managed Markets, and Senior Director, Marketing, for ABILIFY® (aripiprazole) at Bristol-Myers Squibb. Earlier, he worked at GlaxoSmithKline as Vice President, Long Term Care Channel Accounts, and Director of National Accounts, Institutional Sales.

Prior to entering the pharmaceutical industry, John served as Vice President, Clinical and Professional Services, at The Children's Hospital of Philadelphia and assistant administrator at The George Washington University Medical Center in Washington, DC.

John received a B.A. degree from West Chester University and a Master of Health Services Administration degree from The George Washington University.

Jonathan Jarow

Jonathan Jarow

Senior Medical Director, FDA

Read more

Dr. Jonathan P. Jarow is currently the senior medical advisor to the Center Director in CDER at FDA. Jonathan previously served as the director of CDER's Office of Medical Policy, chair of the Medical Policy Council, and as deputy director of the Office of Hematology and Oncology Products. He is a Board Certified Urologist and prior to joining the FDA he was in academic medicine for over 20 years. His last academic appointment was Professor of Urology, Pathology, Radiology, and Molecular Biology & Biochemistry at Johns Hopkins University where he worked for over ten years.

Sean McElligott

Sean McElligott

Global Market Access Lead Dermatology, Janssen

Read more

More information coming soon...

Ana Cespedes

Ana Cespedes

Senior Vice President, Head of Global Market Access & Pricing , EMD Serono

Read more

“PASSION for the project, day –to-day INNOVATION in all areas, a cohesive TEAM with shared VALUES; these are the best ingredients for professional success”

Head of Global Market Access and Pricing for Merck Serono since September 2012, Ana is responsible for developing a global holistic market access strategy, and robust pricing and reimbursement strategies for Merck Serono products. This includes market access plans and guidelines, price analytics, launch pricing and price band setting, as well as acting as the Center of Functional Excellence in Market Access and Pricing.

She started her career in the biotechnology company Serono as Director of Government Affairs in February 2003, managing the development of this area of the company for Spain and Portugal. On June 2007, after the merger between Serono and Merck, Ana was named Corporate Affairs Director of Merck in Spain, in charge of Communications, Innovation & Continuous Improvement, Government Affairs, Market Access, Regulatory Affairs, & Commercial Compliance, a position she held until September 2012, when she was transferred to the Boston office in Rockland, Massachusetts and appointed Head of Market Access and Pricing. She has also served as Managing Director of the Fundación Salud 2000 (2004-2011), a not-for-profit organization dedicated to the promotion of research.

ith 17 years of experience in the healthcare sector, Ana worked as a teacher and researcher at the Universidad Complutense de Madrid (1995-1999), Senior Consultant in HealthCare Strategy at Arthur Andersen (2000-2003), where she worked on numerous projects in the areas of government affairs, market access, strategic positioning and management of healthcare institutions, balanced scorecard implementation, processes redesign and healthcare institutions reorganizations.

PhD in Pharmacy in the areas of genetics and immunology by the UCM (2000), Ana holds a degree in Pharmacy by the UCM (1995), an Executive Master's Degree in Healthcare Institutions Management by Arthur Andersen (2001), and an Executive Degree in General Management by IESE (2009). She graduated as a bachelor and doctorate with high honor. Ana is also professor in the Instituto de Empresa Business School, and founder of the Executive Education Program on Institutional Relations & Market Access (EERIMAS) in Spain.

Riccardo Perfetti

Riccardo Perfetti, MD, PhD

Senior Medical Officer, Vice President Global Medical Affairs, Diabetes Division, Sanofi

Read more

Riccardo Perfetti is the Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi. He trained as an endocrinologist at La Sapienza University, Rome, where he also achieved a PhD in molecular endocrinology in a joint training program with the Johns Hopkins University. He spent ten years at the National Institutes of Health (NIH), Bethesda, working as a Senior Research Fellow and Senior Staff Scientist. In the following eight years Dr Perfetti held a number of clinical, teaching and research positions at the Cedars-Sinai Medical Center and at University of California Los Angeles, where he directed the clinical diabetes program and the basic science diabetes research laboratory. Prior to joining Sanofi in 2007, he held several positions at Amgen Inc, including Director, Department of Medical Sciences within the Translation Medicine Department and Global Development Lead with the General Medicine Development Department. In his current role, he is responsible for the clinical evidence generation strategy for approved and development programs. Dr Perfetti has published numerous articles and is a reviewer for several journals.

Dualities of interest: Riccardo Perfetti is an employee of Sanofi.

Peter Juhn

Peter Juhn

Vice President and Global Head of Value-based Partnerships, Amgen

Read more

Dr. Peter Juhn is Vice President and Global Head of Value-based Partnerships at Amgen. He is responsible for implementing partnerships with payers, care delivery organizations and other key healthcare stakeholders that can lead to more clinical improvement opportunities for patients with serious and debilitating illnesses and result in greater overall value for the healthcare system.

Most recently he was Vice President for Integrated Care Services in the Global Diabetes Division at Sanofi, where he was responsible for creating new patient service platforms and their attendant new business models. He led the business planning efforts for the Sanofi joint venture in diabetes with Verily (aka Google Life Sciences).

Gergana Zlateva

Gergana Zlateva

Vice President, Oncology Market Access, Pfizer

Read more

Gergana Zlateva is a VP, Oncology Market Access at Pfizer. Gergana' s team provides both region-specific and global support in the development and implementation of market access, pricing, reimbursement, and health technology assessment strategies for Pfizer's oncology portfolio. Prior to this role, Gergana was the Payer Insights & Access Cluster Lead for North America, and managed a team of colleagues supporting Pfizer's portfolio and its 3 business: GIP, GEP, and VOC.

During her 14 year tenure with Pfizer, Gergana has held various positions of increasing responsibility covering health economics, outcomes research, and pricing and reimbursement activities across several therapy areas and different geographies. Gergana has led multiple cross-functional teams in preparation of pricing and reimbursement negotiations in developed markets and has presented on behalf of PFE to public and private payer organizations in the EU and US.

Prior to joining Pfizer in 2003, Gergana worked for 5 years on public health, civil society, and business development programs with several United Nations agencies.

Gergana holds a PhD in Economics from Fordham University, NY and a BA and MPA from Southern Illinois University, IL. Gergana's CV includes more than 60 peer-reviewed manuscripts, as well as a number of poster and podium presentations.

Debbie Drane

Debbie Drane

SVP Commercial Development, CSL Behring

Read more

Debbie Drane is the SVP of Global Commercial Development at CSL Behring based in the King of Prussia PA office. In this role she is responsible for market development and life cycle management of the current product portfolio and input into early stage development programs. The global commercial development group also provides support services covering a broad range of services including Global Medical Affairs, Heath Economics & Reimbursement, Competitive Intelligence and Commercial Evaluations. Debbie has been with CSL for over thirty years and has held a variety of senior leadership roles in both Australia and the US. Prior to taking up her current role in September 2014 she led the R&D Licensing & Partnership team based in Parkville, Australia. Debbie spent most of her career in R&D in scientific and management roles and holds a Bachelor of Science Degree from University of Melbourne, Parkville, Australia.

Vivek Garipalli

Vivek Garipalli

CEO, Clover Health

Read more

Vivek Garipalli is the co-founder and CEO of Clover Health, a health insurance company leveraging data to proactively improve health outcomes, filling gaps in care and reducing avoidable costs. Prior to founding Clover, Vivek founded CarePoint Health, a fully integrated healthcare system in New Jersey.

Through his role at CarePoint – whose mission is to serve uninsured and underinsured patient populations – Vivek experienced the misalignment of providers and insurance companies first-hand. Prior to CarePoint, Vivek owned and operated various outpatient facilities. He began his career in finance, holding roles at Credit Suisse First Boston, J.P. Morgan Partners and Blackstone Group.

Vivek is active in health tech, serving as a board member of Flatiron Health and Doctor Evidence. He earned an undergraduate degree in business administration at Emory University with a concentration in entrepreneurship.

Sandy Leonard

Sandy Leonard

Vice President, Medical Evidence and Observational Research, AstraZeneca

Read more

Sandy Leonard is Vice President, Medical Evidence and Observational Research at AstraZeneca who leads a team of epidemiologists, study delivery professionals, and RWE specialists to deliver impactful medical evidence for the entirety of the AstraZeneca portfolio.

Sandy believes the value of evidence is linked inextricably to the ability to improve the lives of patients. She challenges her to team to deliver scientific insight, seek strategic collaboration and ultimately drive innovative, impactful and efficient medical evidence generation.

Throughout her career, Sandy has developed and implemented key corporate strategies focused on the development and application of evidence throughout the healthcare system, including the evolution of AstraZeneca's evidence generation capabilities, establishing AstraZeneca's RWE strategy and collaboration initiatives, as well as leading AstraZeneca's US government reimbursement team during the implementation of the Medicare drug benefit.

Sandy holds an undergraduate degree in Psychology from the University of Wisconsin – Madison and has a Masters in Public Health, from the University of Tennessee – Knoxville.

Vidya Raman-Tangella

Dr. Vidya Raman-Tangella

SVP, Head Innovation Center of Excellence, UnitedHealthcare

Read more

Dr. Vidya Raman-Tangella serves as the head of the UnitedHealthcare Innovation Center of Excellence. Vidya and her team design, develop and scale breakthrough innovations that help address unmet health needs through the use of cutting-edge concepts and technology, including mobile apps and integrated health and wellness programs.

Vidya is a clinician by training and has more than 20 years of experience in the health care field. Prior to her role at UnitedHealthcare, she held a senior management position at Johnson & Johnson, where she led the design of integrated and tailored health and wellness solutions for employers and health plans. In addition, Vidya helped oversee the company's start-up organization, providing expertise about strategic partnerships and enterprise integration.

Vidya has spoken at numerous health care and technology conferences, including the International Consumer Electronics Show (CES), the Healthcare Businesswomen's Association Conference (HBA), the Employer Healthcare Congress, and the “Unleashing Innovation Summit.”.

Vidya holds a bachelor's of medicine degree and a bachelor's of surgery degree from Osmania University in Hyderabad, India, and she earned a master's of health administration from Cornell University in New York.

Andy Gunn

Andy Gunn

Global Head of Evidence Generation Strategy, UCB

Read more

I am currently the Global Head of Evidence Generation Strategy and Global Regulatory Affairs Lead at UCB Biopharmaceuticals, Inc. I have 27 years of experience in the life sciences industry with focus on Real World Evidence (RWE), Regulatory Affairs, and Quality. I have worked previously for such organizations as Novartis, FDA, Otsuka, Amgen, and Eli Lilly.

Ken Carson

Ken Carson

Senior Medical Director, Flatiron Health

Read more

Dr. Ken Carson is a board-certified practicing hematologist and medical oncologist who currently serves as Senior Medical Director at Flatiron Health, where he focuses on real-world evidence generation. Over the course of his career, Dr. Carson's research has focused on the use of large electronic databases to evaluate health care disparities and oncology drug safety.

Dr. Carson also currently practices at Washington University where he specializes in the diagnosis and treatment of patients with hematologic malignancies like lymphomas and leukemia. He joined Washington University School of Medicine's faculty in 2008 and later served as chief of hematology and oncology at the St. Louis Veterans Affairs Medical Center.

Dr. Carson received his medical degree from the University of Southern California, Keck School of Medicine followed by residency training at Duke University, and research and clinical fellowships at Northwestern University. Dr. Carson also received a PhD (with an emphasis in health policy and administration) from the University of Illinois School of Public Health.

Michelle Hoiseth

Michelle Hoiseth

Corporate Vice President, PAREXEL

Read more

Michelle has been working in the drug and medical device development industry for 29 years, through a variety of positions that allowed her to create complete product development plans, design novel regulatory pathways to approval, write both strategic and tactical business development plans, and support product commercialization objectives and life cycle management.  Michelle presently leads the development of PAREXEL's real world data capability, working closely with her colleagues in a multi-disciplinary environment to solve the challenges using real world data in clinical research.  Michelle is committed to leading inclusive, invested, innovative teams to move our industry into the future of clinical product development. 

Register Now

Save $300 with our Early Bird discount. Expires in 2 days


Stanislav Glezer

Stanislav Glezer

Former Vice President of US Medical Affairs, Novo Nordisk

Read more

Stan Glezer, MD, MBA is an industry physician, passionate about optimizing value of pharmaceutical innovation for the patients, through partnering with the healthcare system.

Until recently, he served as Vice President of US Medical Affairs at Novo Nordisk Inc. Prior to joining Novo Nordisk, Stan has worked at Sanofi where, most recently, he led the development, regulatory submission, and launch preparation of Toujeo.

Stan has been involved in multiple initiatives in the areas of Real World Evidence, Outcomes Based Agreements and patient centric business models. He brings with him extensive knowledge at an affiliate and Global level, including leadership roles in post-marketing research, epidemiology, medical communications, HEOR, interfacing with regulatory agencies, market access, marketing, sales and overall lifecycle management.

Although his activities in the past few years were predominantly focused on diabetes, Stan has worked in multiple therapeutic areas, including oncology, immuno-inflammation, obesity, thrombosis, bleeding disorders, rheumatology and rare diseases. He has a strong track record of leading the teams in establishing collaborations with healthcare providers, key opinion leaders, payers, and professional associations.

Stan received his medical training in Russia and has worked in Canada and in France for the past 20 years. He has an MBA from California Coast University and completed his graduate work in Clinical Research at McGill University.

Edmund Pezalla

Edmund Pezalla

Former Vice President for Pharmaceutical Policy and Strategy, Aetna

Read more

Dr. Pezalla in a leading innovator in payer strategy for pharmaceutical and device manufacturers. He focuses on unlocking the value of new products by developing industry-leading approaches to incorporating payer requirements into development programs, technology assessment plans, and value frameworks. He works with a variety of policy and industry groups on cutting edge coverage policy, innovations in value-based payments, and adaptive regulatory and market entry pathways.

Dr. Pezalla is the former Vice President for Pharmaceutical Policy and Strategy in the Office of the Chief Medical Officer at Aetna. In this position Dr. Pezalla developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna's framework for innovative contracts, and developed Aetna's public policy positions on drug and device coverage.

Tom Abbott

Thomas Abbott

Global Head, Real World Informatics Capabilities and Alliances, Astellas

Read more

More information coming soon...

Ed Schoonveld

Ed Schoonveld

Principal, Value & Access, ZS

Read more

More information coming soon...

Aaron Mitchell

Aaron Mitchell

Principal, R&D Excellence, ZS

Read more

More information coming soon...

Nneka Onwudiwe

Nneka C. Onwudiwe

PRO/PE Regulatory Review Officer, US Government

Read more

Nneka C. Onwudiwe, PhD, PharmD, MBA received her doctorate in Pharmacy from the University of Maryland School of Pharmacy, PhD in Health Services Research with a specialization in Pharmacoeconomics from the University of Maryland School of Pharmacy, and a MBA (Honors) from the University of Baltimore. In addition, she received an honor of Rho Chi in Pharmacy in 2002 and an honor of Beta Gamma Sigma in Business Administration in 2012.

Dr. Onwudiwe is the technical expert and point of contact in the review of patient-reported outcomes (PRO), pharmacoeconomics (PE), and other type of claims in prescription drug promotion for the Division of Advertising and Promotion Review II (DAPR II) within the Office of Prescription Drug Promotion at the Food and Drug Administration (FDA).

Jack Sheehan

Jack Sheehan

RWE Pragmatic Trial Team Lead, Janssen

Read more

Jack Sheehan works as a Real-World Evidence team leader at Janssen Scientific Affairs to effectively and efficiently drive high-priority, prospective, real-world evidence research projects from early stage development through execution and completion in close partnership with other scientific function. He supports the Central Nervous System, Infectious Disease, and Metabolics therapeutic areas.

He has worked across a variety of Medical Affairs functions over 11 years in the pharmaceutical industry. Jack has co-authored 38 papers, ranging from basic science to clinical science to epidemiology and policy. He holds a PhD in Molecular Pharmacology from SUNY Stony Brook and a BS in Pharmacy from Rutgers. He also completed post-doctoral training in Pathophysiology at the University of Pennsylvania and an MBA specialized in economics at New York University.

Deborah Kilpatrick

Deborah Kilpatrick

CEO, Evidation Health

Read more

More information coming soon...

Margaret McDonald, PhD, MS, MT(ASCP)

Margaret McDonald, PhD

Senior Director, Real World Data and Analytics, Patient & Health Impact, Pfizer

Read more

Margaret McDonald, PhD, MS, MT(ASCP) is a Senior Director in the Real World Data and Analytics (RWDnA) group, part of the Patient and Health Impact function at Pfizer. In her current position, Margaret supports the Internal Medicine, Rare Disease, and Consumer portfolio in the development and delivery of insights using real world data and analytics. Her work includes using rapid cycle query tools for analyses leading to potential studies, consultation on study design and uses of data, presenting at internal and external meetings, and as RWD liaison to Pfizer EU and LATAM country colleagues. Her research focus includes population studies, burden of illness, gaps in healthcare services, and healthcare disparities. Prior to this position, Margaret led the Population Health efforts within Outcomes Research, creating reports used externally by Pfizer colleagues and external organizations.

Margaret has been employed at Pfizer for 16 years. She has a PhD in epidemiology from the University of Massachusetts, and holds a Masters degree in biology from the University of Hartford. Prior to Pfizer, Dr. McDonald was an assistant professor at the Center for Community Health at the University of Southern Mississippi in Hattiesburg; worked at an occupational epidemiology firm; and completed an internship at the Centers for Disease Control and Prevention at the National Center for Health Statistics. Dr. McDonald has also held positions of laboratory management at community hospitals.

Ken Booth

Ken Booth

Managing Director, Huron Consulting

Read more

Ken serves life sciences clients across a variety of strategic questions, with emphasis on new therapy commercialization, brand and portfolio strategy, and market access. After years of management consulting to life sciences companies and a prior career in scientific research, Ken bridges the commercial, clinical, and regulatory complexities facing the industry. His clients span large pharmaceutical and early-stage biotechnology companies, and include not only manufacturers but also distributors, specialty pharmacies, and service providers. Ken is active in multiple therapeutic areas including oncology, neurology, immunology, infectious disease, cardiology, hematology, respiratory, nephrology, psychiatry, pain management, and genetic rare diseases. Ken has experience in commercializing a wide variety of generic and branded small molecules, biologics, cellular, and gene therapies. Ken's global experience includes the US, EMEA, Asia Pacific, and Latin America.

Andrew Hobbs

Andrew Hobbs

Managing Director, Pope Woodhead

Read more

Andrew is Managing Director of PW. He has more than 25 years' experience in consulting to the pharmaceutical industry, with a particular expertise in value strategy and market access. He has strong links with the University of York and Cambridge University. Prior to joining PW in 2001 he spent six years as a management and technology consultant at Cambridge Consultants, an Arthur D. Little subsidiary

Bruce Lavin

Bruce Lavin

Vice President and Head – Medical Affairs, Neurology Patient Value Unit and Head of External Engagement and Policy, UCB

Read more

Dr. Bruce Lavin is Vice President and Head – Medical Affairs, Neurology Patient Value Unit and Head of External Engagement and Policy. He is also an actively practicing physician in Internal Medicine, Infectious Diseases, and Critical Care.

Dr. Lavin has more than 30 years of Clinical and Academic experience in Internal Medicine, Infectious Diseases, and Trauma, including over 19 years of Pharmaceutical Industry experience. He has lead Medical Affairs and Clinical Development programs and multiple therapeutic divisions for major pharmaceutical companies in the areas of Neurology, Immunology, Virology and Anti-Infectives.  Previously, Dr. Lavin was the Vice President and Therapeutic Head for Bristol-Myers Squibb where he led the U.S. clinical activities for HIV, HBV, HCV, as well as in Rheumatology and Transplant. Prior to Bristol-Myers Squibb, he held senior medical executive roles for both Novartis and Sanofi-Aventis in the areas of Infectious Disease, Immunology, Transplantation, Virology and the Central Nervous System. Dr. Lavin previously served as Head of Clinical Medicine in the Northern California VA system. He has also served 36 years as a Navy Medical Officer, directing Academic Clinical Medicine, US Marine Corps operational support, and Military Medical Research, retiring as Captain in the US Navy.

Dr. Lavin holds a Bachelor’s degree from the University of California Irvine and a Master’s Degree of Public Health from the University of California, Los Angeles. He received his Medical Degree from the F. Herbert School of Medicine in Maryland. He is Board Certified in Internal Medicine and Infectious Diseases and has certifications in Aerospace Medicine, Outcomes Research, and Health Law.

Eduardo Valencia Tirapu

Eduardo Valencia Tirapu

Linguist and Data Analytics Manager, MeaningCloud

Read more

Linguist and Data Analytics Manager at MeaningCloud. Writer and international speaker at conferences in the USA, France, Spain, Turkey, United Kingdom Germany, Austria and Italy. The author of the book DATA COACHING (http://eduardovalencia.com/datacoaching).

Reg Waldeck

Reg Waldeck

Market Access Strategy Leader, Bayer

Read more

More information coming soon...

Don't miss out - register now

Only 2 days left to save $300 with our Early Bird discount. Don't miss out!